Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fulacimstat
- Development stage
- Phase 2
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Fulacimstat is a selective, orally available small molecule chymase inhibitor developed as a first-in-class treatment option for the inhibition of adverse cardiac remodeling in patients with left ventricular dysfunction after acute myocardial infarction. It has also been investigated for diabetic kidney disease and type 2 diabetes mellitus. Fulacimstat demonstrated safety and tolerability in clinical trials, but did not meet efficacy endpoints in phase II studies. The drug was developed by Bayer HealthCare[3][4][5][7].
- Other names
- fulacimstat
02
Targets
CMA1 (Chymase)
Beyond the preview
Go deeper on fulacimstat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fulacimstat.